$AXSM
Axsome Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023004728 Filed on February 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $94.58M $24.37M $0.00
YoY Change
Cost Of Revenue $7.556M $2.291M $5.200M
YoY Change
Gross Profit $87.02M $22.08M -$5.200M
YoY Change
Gross Profit Margin 92.01% 90.6%
Selling, General & Admin $74.19M $61.50M $159.3M
YoY Change 188.64% 226.65% 138.95%
% of Gross Profit 85.26% 278.51%
Research & Development $17.79M $14.69M $57.95M
YoY Change 41.38% 6.61% -0.2%
% of Gross Profit 20.45% 66.54%
Depreciation & Amortization $90.00K $1.692M $263.4K
YoY Change 145.66% 5351.42% 245.04%
% of Gross Profit 0.1% 7.66%
Operating Expenses $91.98M $82.00M $217.2M
YoY Change 140.24% 151.46% 74.17%
Operating Profit -$6.374M -$59.92M -$179.8M
YoY Change -83.35% 44.18%
Interest Expense -$2.264M -$1.323M -$7.335M
YoY Change 68.52% -3.32% 28.77%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$8.638M -$61.24M -$187.1M
YoY Change -78.2% 80.24% 43.5%
Income Tax $2.600M $0.00
% Of Pretax Income
Net Earnings -$11.22M -$61.24M -$187.1M
YoY Change -71.69% 80.24% 43.5%
Net Earnings / Revenue -11.86% -251.28%
Basic Earnings Per Share -$0.26 -$4.60
Diluted Earnings Per Share -$0.26 -$1.41 -$4.60
COMMON SHARES
Basic Shares Outstanding 43.52M 43.43M 40.66M
Diluted Shares Outstanding 43.52M 40.66M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $246.5M $200.8M $200.8M
YoY Change 191.02% 132.26% 132.26%
Cash & Equivalents $246.5M $200.8M $200.8M
Short-Term Investments
Other Short-Term Assets $5.201M $2.781M $2.781M
YoY Change 145.08% 6039.7% 6039.7%
Inventory $7.940M $4.320M $4.320M
Prepaid Expenses
Receivables $44.79M $37.70M $37.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $304.4M $245.6M $245.6M
YoY Change 250.63% 183.92% 183.92%
LONG-TERM ASSETS
Property, Plant & Equipment $703.0K $722.5K $1.143M
YoY Change 52.51% 154.54% 21.06%
Goodwill $10.31M $10.31M
YoY Change
Intangibles $58.09M $59.66M
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.52M $14.72M $14.72M
YoY Change 4706.91% 4458.89% 4458.89%
Total Long-Term Assets $84.73M $85.83M $85.83M
YoY Change 4796.74% 6675.08% 6675.07%
TOTAL ASSETS
Total Short-Term Assets $304.4M $245.6M $245.6M
Total Long-Term Assets $84.73M $85.83M $85.83M
Total Assets $389.2M $331.5M $331.5M
YoY Change 339.45% 277.6% 277.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $35.77M $38.61M $38.61M
YoY Change 184.0% 193.59% 193.59%
Accrued Expenses $58.88M $52.06M $52.06M
YoY Change 392.55% 424.97% 424.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $100.7M $96.56M $96.56M
YoY Change 309.99% 318.64% 318.64%
LONG-TERM LIABILITIES
Long-Term Debt $147.6M $94.26M $94.26M
YoY Change 199.35% 92.01% 92.01%
Other Long-Term Liabilities $29.10M $31.10M $31.10M
YoY Change
Total Long-Term Liabilities $147.6M $94.26M $125.4M
YoY Change 199.35% 92.01% 155.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $100.7M $96.56M $96.56M
Total Long-Term Liabilities $147.6M $94.26M $125.4M
Total Liabilities $277.4M $221.9M $221.9M
YoY Change 275.52% 207.56% 207.56%
SHAREHOLDERS EQUITY
Retained Earnings -$607.6M -$596.3M
YoY Change 35.38% 45.72%
Common Stock $719.4M $705.9M
YoY Change 55.19% 66.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.8M $109.6M $109.6M
YoY Change
Total Liabilities & Shareholders Equity $389.2M $331.5M $331.5M
YoY Change 339.45% 277.6% 277.6%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$11.22M -$61.24M -$187.1M
YoY Change -71.69% 80.24% 43.5%
Depreciation, Depletion And Amortization $90.00K $1.692M $263.4K
YoY Change 145.66% 5351.42% 245.04%
Cash From Operating Activities -$5.821M -$27.56M -$116.5M
YoY Change -82.17% -4.43% 7.66%
INVESTING ACTIVITIES
Capital Expenditures $71.00K $180.9K $702.1K
YoY Change -66.78% 128.29%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$53.00M
YoY Change
Cash From Investing Activities -$71.00K -$180.9K -$53.70M
YoY Change -66.78% 17361.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $236.8M
YoY Change 3183.08%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 51.57M 1.066M 284.6M
YoY Change 65.8% 54.36% 2456.96%
NET CHANGE
Cash From Operating Activities -5.821M -27.56M -116.5M
Cash From Investing Activities -71.00K -180.9K -53.70M
Cash From Financing Activities 51.57M 1.066M 284.6M
Net Change In Cash 45.67M -26.68M 114.4M
YoY Change -2687.6% -5.23% -217.42%
FREE CASH FLOW
Cash From Operating Activities -$5.821M -$27.56M -$116.5M
Capital Expenditures $71.00K $180.9K $702.1K
Free Cash Flow -$5.892M -$27.74M -$117.2M
YoY Change -82.07% -3.8% 8.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001579428
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37635
CY2022 dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
22 Cortlandt Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
CY2022 dei City Area Code
CityAreaCode
212
CY2022 dei Local Phone Number
LocalPhoneNumber
332-3241
CY2022 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2022 dei Trading Symbol
TradingSymbol
AXSM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
1200000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43516501
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
New York, New York
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200841955
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86472854
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37698868
CY2022Q4 us-gaap Inventory Net
InventoryNet
4319921
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2780665
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45286
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
283846
CY2022Q4 us-gaap Assets Current
AssetsCurrent
245641409
CY2021Q4 us-gaap Assets Current
AssetsCurrent
86518140
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
722515
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
420298
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
660162
CY2022Q4 us-gaap Goodwill
Goodwill
10310000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59660772
CY2022Q4 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
14721101
CY2021Q4 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
322910
CY2022Q4 us-gaap Assets
Assets
331476095
CY2021Q4 us-gaap Assets
Assets
87785058
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38605312
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13149329
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
51630813
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
424673
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620675
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
5900000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
96560798
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23065184
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
31100000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94258888
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022Q4 us-gaap Liabilities
Liabilities
221919686
CY2021Q4 us-gaap Liabilities
Liabilities
72154706
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43498617
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43498617
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37816794
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37816794
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4350
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3782
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
705884795
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
424825655
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-596332736
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409199085
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109556409
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
331476095
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87785058
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50037106
CY2022 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
5197595
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57947447
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58060725
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70244579
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
159253661
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
66646205
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28896749
CY2022 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
3298230
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4139228
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
229836161
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
124706930
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
99141328
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-179799055
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-124706930
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-99141328
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
-7334596
CY2021 us-gaap Investment Income Net
InvestmentIncomeNet
-5696062
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
-2565838
CY2020 axsm Income From Nyc Biotechnology Credit
IncomeFromNYCBiotechnologyCredit
53578
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-187133651
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-130402992
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.60
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.60
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.47
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.47
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.77
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.77
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40655941
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40655941
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37618599
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37618599
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37206928
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37206928
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14756206
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1049849
CY2020 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6
CY2020 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
884216
CY2020 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
14125506
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20801380
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4402400
CY2021 axsm Stock Vested During Period Value Restricted Common Stock Award
StockVestedDuringPeriodValueRestrictedCommonStockAward
1
CY2021 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
7212367
CY2021 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
175713
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-130402992
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37726158
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-307549
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6251173
CY2022 axsm Stock Vested During Period Value Restricted Common Stock Award
StockVestedDuringPeriodValueRestrictedCommonStockAward
0
CY2022 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
236788056
CY2022 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
826153
CY2022 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
531832
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-187133651
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109556409
CY2022 us-gaap Profit Loss
ProfitLoss
-187133651
CY2021 us-gaap Profit Loss
ProfitLoss
-130402992
CY2020 us-gaap Profit Loss
ProfitLoss
-102900600
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
37726158
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
20801380
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14756206
CY2020 axsm Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
7155337
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4139228
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1482678
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1077015
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
786750
CY2022 us-gaap Depreciation
Depreciation
263440
CY2021 us-gaap Depreciation
Depreciation
76350
CY2020 us-gaap Depreciation
Depreciation
23864
CY2022 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
3298230
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1161505
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1079313
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
53854
CY2022 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-1117643
CY2021 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-1181620
CY2020 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
8967
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
37698868
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1330916
CY2022 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
2735379
CY2021 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-103087
CY2020 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-264722
CY2022 axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
3944196
CY2021 axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
5535
CY2020 axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
177500
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25455983
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-354693
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2560697
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
43922633
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
581931
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2235878
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116510798
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108225764
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78456569
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
702109
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
307549
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45891
CY2022 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
53000000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53702109
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45891
CY2022 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
45000000
CY2020 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
50000000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
487160
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
309340
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1102609
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
21660000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236788056
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7212367
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14125506
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6251173
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4402400
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1049849
CY2022 axsm Payment Of Contingent Consideration
PaymentOfContingentConsideration
-2438230
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
531831
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
175713
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
284582008
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11129714
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42412746
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
114369101
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-97403599
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36089714
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86472854
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183876453
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
219966167
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200841955
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86472854
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183876453
CY2022 us-gaap Interest Paid Net
InterestPaidNet
7686292
CY2021 us-gaap Interest Paid Net
InterestPaidNet
4625208
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2097292
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
561380
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1793328
CY2022 axsm Fair Value Of Contingent Consideration In A Business Combination
FairValueOfContingentConsiderationInABusinessCombination
37000000
CY2020 axsm Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
884216
CY2022Q4 axsm Number Of Not Yet Approved Product Candidates
NumberOfNotYetApprovedProductCandidates
3
CY2022Q4 axsm Number Of Approved Products
NumberOfApprovedProducts
2
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-596300000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; accounting for acquisitions; impairments goodwill and intangible assets; contingent consideration; chargebacks, cash discounts, sales rebates, returns and other adjustments; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</span></p>
CY2022 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
90 days or less
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
200800000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk -</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2022, the majority of the Company’s cash was held by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception and does not believe that it is exposed to any significant credit risk with respect to cash and cash equivalents. See Accounts Receivables, net below for further information.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Risk, Other-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have a limited number of contract manufacturers for our products. At times we may have only one manufacturer or supplier for a product.</span></p>
CY2022Q4 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
CY2022 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 axsm Accounts Receivable Allowance Reserve For Variable Consideration
AccountsReceivableAllowanceReserveForVariableConsideration
9100000
CY2022 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
5200000
CY2022 us-gaap Revenues
Revenues
0
CY2022 us-gaap Advertising Expense
AdvertisingExpense
35300000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4139228
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59660772
CY2021 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
74065000
CY2022 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
51670000
CY2021 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-211571000
CY2022 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-283831000
CY2022 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
11897000
CY2022 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
-1587000
CY2022Q4 us-gaap Goodwill
Goodwill
10310000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
63800000
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2022Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4714388
CY2021Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2416897
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6374760
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6392226
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6374760
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6374760
CY2022Q4 axsm Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
34144266
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
59660772
CY2022 axsm Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Initial Estimate
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEstimate
36140000
CY2022 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
3298230
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-2438230
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
37000000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11283646
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4050236
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1616541
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2473058
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
13964402
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1590350
CY2022Q4 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
18027810
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2022Q4 us-gaap Inventory Net
InventoryNet
4319921
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
13707889
CY2022Q4 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
18027810
CY2021Q4 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
2442700
CY2022Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
26544510
CY2022Q4 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
6596409
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
875319
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
385347
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
51630813
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2022Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
1362733
CY2021Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
706407
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
2103845
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1616885
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94258888
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
8176264
CY2021 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4616597
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2362083
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
668051
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
554493
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
469676
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
15202884
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
79797116
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company entered into a lease for office space at 22 Cortlandt St, New York, NY consisting of the 16th floor effective August 1, 2020. In August 2022, the Company entered into an agreement to extend the lease of 22 Cortlandt Street through April 30, 2023.
CY2022 axsm Lease Commencement Date
LeaseCommencementDate
2020-08-01
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extend the lease of 22 Cortlandt Street through April 30, 2023
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1255165
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1175139
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
870275
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1207837
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1147692
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
47821
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
427875
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
427875
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3202
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
424673
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-187133651
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-130402992
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40655941
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40655941
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37618599
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37618599
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37206928
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37206928
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.60
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.60
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.47
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.47
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.77
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.77
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7354899
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5432543
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3885524
CY2022 axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5090377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.89
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2222866
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
38.62
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
340149
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.38
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
317942
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
39.50
CY2022 axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
37424
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
54.76
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6617728
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.80
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
300653467
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6617728
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
31.80
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
300653467
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3470813
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.43
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
193768216
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.18
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
39.64
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
36.77
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
95700000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6169
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13200000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13500000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9400000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37726158
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20801380
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14756206
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
69656
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.21
CY2020 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
15541
CY2020 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
80.43
CY2020 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
69656
CY2020 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
7.21
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
CY2022 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
35255
CY2022 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
31.91
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
50796
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
46.75
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
69656
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
458000000
CY2022Q4 axsm Operating Loss Carryforwards Foreign
OperatingLossCarryforwardsForeign
7800000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
96156250
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
76470431
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
2794785
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
88480
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
32029378
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
47672157
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
11027745
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
13228425
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15015642
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14455797
CY2022Q4 axsm Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
318798
CY2021Q4 axsm Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
4117655
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
10422110
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2113054
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1479728
CY2022Q4 axsm Deferred Tax Assets Setion174 Capitlization
DeferredTaxAssetsSetion174Capitlization
14540848
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
109988
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
219760
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
184528598
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
157732433
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
104001
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
224958
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
104001
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
224958
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
184424597
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
157507475
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
26900000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
49600000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
39700000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.140
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.137
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.018
CY2022 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.003
CY2021 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.001
CY2020 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.013
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.029
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.239
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.380
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.384
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0

Files In Submission

Name View Source Status
axsm-20221231_cal.xml Edgar Link unprocessable
0000950170-23-004728-index-headers.html Edgar Link pending
0000950170-23-004728-index.html Edgar Link pending
0000950170-23-004728.txt Edgar Link pending
0000950170-23-004728-xbrl.zip Edgar Link pending
axsm-20221231.htm Edgar Link pending
axsm-20221231.xsd Edgar Link pending
axsm-ex21_1.htm Edgar Link pending
axsm-ex23_1.htm Edgar Link pending
axsm-ex31_1.htm Edgar Link pending
axsm-ex31_2.htm Edgar Link pending
axsm-ex32_1.htm Edgar Link pending
axsm-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img239322041_0.jpg Edgar Link pending
img239322041_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
axsm-20221231_htm.xml Edgar Link completed
axsm-20221231_def.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
axsm-20221231_pre.xml Edgar Link unprocessable
axsm-20221231_lab.xml Edgar Link unprocessable